Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
- Conditions
- First Posted Date
- 2002-08-08
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 40
- Registration Number
- NCT00043264
- Locations
- 🇺🇸
University of Texas Medical School, Houston, Texas, United States
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
- Conditions
- Interventions
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2011-08-03
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 98
- Registration Number
- NCT00023374
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
🇨🇦University of British Columbia, Vancouver, British Columbia, Canada
🇺🇸Washington, D.C. VAMC, Washington, District of Columbia, United States
The Treatment of Tuberculosis in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 650
- Registration Number
- NCT00001033
- Locations
- 🇺🇸
Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
🇺🇸Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 2000
- Registration Number
- NCT00000638
- Locations
- 🇺🇸
Moses H Cone Memorial Hosp, Greensboro, North Carolina, United States
🇺🇸State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 2000
- Registration Number
- NCT00000636
- Locations
- 🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Philadelphia FIGHT, Philadelphia, Pennsylvania, United States
🇺🇸Boston Dept of Health and Hosps, Boston, Massachusetts, United States
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 525
- Registration Number
- NCT00000796
- Locations
- 🇺🇸
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 90
- Registration Number
- NCT00000641
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 50
- Registration Number
- NCT00000950
- Locations
- 🇺🇸
Emory Univ, Atlanta, Georgia, United States
🇺🇸Beth Israel Med Ctr, New York, New York, United States
🇺🇸Queens Med Ctr, Honolulu, Hawaii, United States
Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- National Jewish Health
- Target Recruit Count
- 50
- Registration Number
- NCT00004689
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.